Serono Rebif Efficacy Gain Over Avonex Likely To Persist Past 48 Weeks–FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The efficacy advantage of Serono’s multiple sclerosis agent Rebif (interferon beta-1a) over Biogen’s Avonex (interferon beta-1a) will likely be maintained beyond 48 weeks, FDA reviewers concluded in review documents for the BLA.